Press releases Oct 07, 2021
Nightingale receives CE marking for its at-home blood collection kit
Press release, 7 October 2021 at 9:30 a.m. (EEST)
Nightingale Health Plc (“Nightingale”) has received a CE marking for its at-home blood collection kit that it uses in its at-home solution. The at-home blood collection kit is CE marked under the category of in vitro diagnostic medical devices, and the CE marking covers the packaging, the equipment used for the blood collection and instructions for use.
Nightingale has previously distributed the at-home blood collection kit in its at-home pilot under the CE marking registered by the device manufacturer, but now the CE marking registered by Nightingale enables Nightingale to operate more independently and rapidly when scaling its at-home solutions to different international markets. Registering the CE marking for the at-home blood collection kit allows Nightingale to make changes to the product according to a flexible process, which makes it possible to adjust to the needs of different markets and business partners.
Teemu Suna, CEO and Co-founder of Nightingale:
“Our own CE marking for the at-home blood collection kit is an important part of the global expansion plan of the at-home testing offering, as having more control of the product enables rapid market entries by adapting to local needs. Applying for the CE marking was a systematic extension to our quality strategy, which ensures that our products and services always correspond to the highest quality standards.”
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale